You are here: Industry Insights > BMS

News List

Broad-spectrum anti-cancer drug "returns" to China, and the market landscape has already changed drastically Yefenghong
May 27, 2024
Paclitaxel, a natural product extracted from taxus chinensis, acts on the microtubule to inhibit the mitosis of tumor cells and is one of the most important broad-spectrum chemotherapy drugs.
Joining Forces with Zai Lab: What is the Remaining Market Potential for Opdivo in China? Yefenghong
March 06, 2024
Bristol Myers Squibb (BMS) recently announced the transfer of sales rights for one of its core products, the PD-1 monoclonal antibody Opdivo (nivolumab), in select provinces within China to the local biotechnology firm Zai Lab Limited (ZLAB).
O-drug Approved as First-line Immunotherapy for Gastric Cancer and What Other Domestic Counterparts to Expect PharmaSources/Yefenghong
May 08, 2021
O-drug is the first approved immunotherapy for first-line treatment of gastric cancer.
US clears BMS' Opdivo as first adjuvant therapy for bladder cancer firstwordpharma
August 23, 2021
Bristol Myers Squibb said Friday that the FDA has expanded Opdivo's (nivolumab) urothelial carcinoma (UC) indication to include adjuvant use in high-risk patients, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.
MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma pharmatimes
August 06, 2021
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb's (BMS) Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for the first-line treatment of adult patients with unresectable malignant pleural ...
BMS withdraws Istodax as a treatment for peripheral T-cell lymphoma pharmatimes
August 06, 2021
Celgene (now a subsidiary of Bristol Myers Squibb) received accelerated FDA approval in 2011 for Istodax (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adult patients who ...
BMS Completes Sale of Couvet Site to WuXi STA contractpharma
August 05, 2021
Bristol Myers Squibb has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec.
WuXi STA completes acquisition of its first European facility cphi-online
August 05, 2021
The purchase of BMS's Couvet, Switzerland facility adds commercial-scale production capacity for capsule and tablet dosage forms
WuXi STA Completes Acquisition of BMS Manufacturing Facility contractpharma
August 04, 2021
State-of-the-art facility in Couvet, Switzerland enhances WuXi STA's drug product capacity in Europe.
EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients pharmatimes
August 03, 2021
Bristol Myers Squibb (BMS) has announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with oesophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page